DSIP

Sleep & Stress RecoveryResearch Only

Decades of research with moderate evidence quality, but the peptide itself shows surprisingly little direct biological activity in controlled settings. The disconnect between promising sleep studies and lack of measurable intrinsic activity raises questions about the underlying mechanisms.

Sleep disorder researchers and chronobiology labs investigating natural sleep regulation, particularly those studying delta-wave sleep patterns and stress-induced insomnia.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

30 total, 16 human

What is DSIP?

Originally discovered in rabbit brain tissue in the 1970s, this nine-amino acid neuropeptide has attracted decades of research focused on sleep disorders and stress-related conditions. Sleep researchers and neuroscientists have investigated DSIP primarily for its apparent ability to promote deeper, more restorative sleep phases without the sedative effects of traditional sleep aids.

DSIP appears to work by crossing the blood-brain barrier and interacting with specific receptors in brain regions that control circadian rhythms and stress hormone release. Rather than simply knocking you out like a sleeping pill, it seems to help the brain naturally shift into deeper delta-wave sleep phases while potentially reducing cortisol and other stress hormones that can disrupt normal sleep architecture.

What the Research Shows

30 total studies including 16 human trials, but only 5 randomized controlled trials, and the evidence base remains limited despite decades of investigation.

Among 21 human studies (5 RCTs), DSIP injections demonstrated improvements in sleep structure and insomnia symptoms with repeated dosing, though the evidence base is limited; DSIP-like immunoreactivity was decreased in dementia and neurological diseases compared to controls, but DSIP itself lacks documented intrinsic biological activity in controlled studies.